Search
Natamycin
go.drugbank.com/drugs/DB00826ApprovedInvestigationalIt is used for a variety of fungal infections, mainly topically. [PubChem]
Categories: Antifungals for Topical Use, Antifungals for Dermatological UseRusfertide
go.drugbank.com/drugs/DB17724ApprovedInvestigational[L64113] It is the first hepcidin mimetic approved for polycythemia vera.[L64113] … [L64098] The FDA approved rusfertide on August 28, 2026 for the treatment of erythrocytosis in adults with polycythemia vera, a blood cancer.
Radium Ra-223
go.drugbank.com/drugs/DB12813InvestigationalRadium 223 is under investigation in clinical trial NCT02463799 (Ph 2 Study of Sipuleucel-T W/ or W/O Radium-223 in Men With Asymptomatic or Minimally Symptomatic Bone-MCRPC).
Esmolol
go.drugbank.com/drugs/DB00187ApprovedInvestigationalWithdrawnOther esmolol formulations are still available for use.[L43942] … The FDA withdrew its approval for the use of all parenteral dosage form drug products containing esmolol hydrochloride that supply 250 milligrams/milliliter of concentrated esmolol per 10-milliliter ampule
Synonyms: (±)-methyl p-(2-hydroxy-3-(isopropylamino)propoxy)hydrocinnamate, methyl p-(2-hydroxy-3-(isopropylamino)propoxy)hydrocinnamateCategories: Antihypertensive Agents Indicated for Hypertension, Cytochrome P-450 SubstratesIngenol mebutate
go.drugbank.com/drugs/DB05013ApprovedWithdrawnPicato gel is indicated for the topical treatment of actinic keratosis. Before approval, ingenol mebutate was called PEP005 as an investigational drug. … PEP005 is a selective small molecule activator of protein kinase C (PKC) extracted from the plant Euphorbia peplus, whose sap has been used as a traditional medicine for the treatment of skin conditions
SF1126
go.drugbank.com/drugs/DB05210InvestigationalSF1126 is an integrin-targeted PI3 kinase inhibitor.
Loncastuximab tesirine
go.drugbank.com/drugs/DB16222ApprovedInvestigationalRelapsed and refractory B-cell acute lymphoblastic leukemia (B-ALL) are a therapeutic challenge for patients who have undergone prior systemic therapies with limited success. … [A234444] On April 23 2021, the Food and Drug Administration granted accelerated approval for the antibody-drug conjugate, loncastuximab tesirine-lpyl, also known as Zynlonta.
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesEthynodiol diacetate
go.drugbank.com/drugs/DB00823ApprovedA synthetic progestational hormone used alone or in combination with estrogens as an oral contraceptive. … Although etynodiol or ethynodiol are sometimes used as a synonym for ethynodiol diacetate, what is usually being referred to is actually ethynodiol diacetate and not ethynodiol (which is a separate drug
Categories: Hormonal Contraceptives for Systemic Use, Cytochrome P-450 SubstratesMeningococcal polysaccharide vaccine group A
go.drugbank.com/drugs/DB13889ApprovedInvestigationalIt is subcutaneously administered as an active immunization against the invasive meningococcal disease caused by the serogroup A.
Mixtures: MENVEO POWDER & SOLUTION FOR SOLUTION FOR INJECTION, Menveo Powder and Solution for Solution for InjectionPozelimab
go.drugbank.com/drugs/DB15218ApprovedInvestigational[L47880] The pathophysiology of this disease is mainly attributed to the deficiency of the CD55 protein, which is the main regulator of the complement cascade.[A261105,A261110,A261115]. … [L47850] In August 18, 2023, pozelimab was approved by the FDA for the treatment of CHAPLE disease. It is currently the only treatment explicitly indicated for CHAPLE disease.[L47875]